Theory Paper IDrNB Cardiology – Theory Notes

MANAGEMENT OF THE FAILING FONTAN CIRCULATION

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ITHE FONTAN PHYSIOLOGY AND THE “FAILING FONTAN” DEFINITION

  • The Fontan Circulatory Paradox: The Fontan operation (Total Cavopulmonary Connection [TCPC]) routes systemic venous return from the SVC and IVC directly into the pulmonary arterial tree without a subpulmonary ventricular pump. Consequently, the circulation operates under a fundamental physiological paradox: chronic upstream systemic venous hypertension (CVP 12 to 20 mmHg) required to drive passive transpulmonary flow, coupled with chronic downstream systemic ventricular preload deprivation and low cardiac output.
  • Definition of the “Failing Fontan”: A multi-organ clinical syndrome of circulatory attrition characterized by progressive decline in functional capacity, refractory systemic venous congestion (ascites, edema), worsening cyanosis, arrhythmias, or lymphatic/end-organ failure (Protein-Losing Enteropathy, Plastic Bronchitis, or Fontan-Associated Liver Disease)—which frequently occurs even when single-ventricle systolic ejection fraction is completely preserved.

IIFOUR DISTINCT HEMODYNAMIC PHENOTYPES OF FONTAN FAILURE (ADAPTED FROM BOOK ET AL.)

  • Phenotype I — Reduced Systolic Function (Failing Single Ventricle with Low EF): Classic systolic pump failure, most common when the systemic single ventricle is a morphological Right Ventricle (e.g., Hypoplastic Left Heart Syndrome) subjected to systemic afterload and chronic systemic atrioventricular (tricuspid) valve regurgitation.
  • Phenotype II — Preserved Systolic Function with Elevated Ventricular End-Diastolic Pressure (Diastolic / Restrictive Failure): Progressive myocardial hypertrophy, interstitial fibrosis, and loss of ventricular compliance raise systemic ventricular end-diastolic pressure (VEDP greater than 12 to 15 mmHg), which backs up across the lungs to mandate dangerously high Fontan venous pressures.
  • Phenotype III — Normal Heart with Elevated Pulmonary Vascular Resistance or Pathway Obstruction (“Pulmonary / Conduit Failure”): Preserved ventricular systolic and diastolic function, but passive flow is blocked by anatomical stenosis in the Fontan conduit/baffle or branch pulmonary arteries, pulmonary vein compression, or maladaptive pulmonary vascular remodeling (elevated PVR) from non-pulsatile flow.
  • Phenotype IV — Abnormal Lymphatics with Near-Normal Hemodynamics (“Lymphatic Failure”): Decompression of pressurized thoracic duct and hepatoduodenal lymphatics into low-resistance mucosal lumen spaces, manifesting as Protein-Losing Enteropathy (PLE) or Plastic Bronchitis (PB).
Failing Fontan Phenotype CVP / Fontan Pressure Ventricular EDP (PAWP) Cardiac Output Primary Pathophysiological Driver
Type I: Systolic Failure Elevated (>15 mmHg) Elevated (>12 mmHg) Low Morphological RV systolic failure; severe AV valve regurgitation
Type II: Diastolic Failure Elevated (>15 mmHg) Markedly Elevated (>15 mmHg) Low / Normal Stiff, fibrotic non-compliant single ventricle
Type III: Fontan / PA Impedance Markedly Elevated (>18 mmHg) Normal (<10 mmHg) Low Conduit/PA stenosis; elevated PVR (wide transpulmonary gradient >6–8 mmHg)
Type IV: Lymphatic Failure Mild-Moderately Elevated Normal / Mildly Elevated Normal / High Thoracic duct hypertension -> PLE (enteric leak) or Plastic Bronchitis (airway leak)

IIIDIAGNOSTIC WORKUP (ESC 2020 ACHD / AHA 2019 GUIDELINES)

  • Invasive Cardiac Catheterization (Class I Mandatory at Low Threshold): Any Fontan patient presenting with unexplained decline, edema, ascites, PLE, plastic bronchitis, worsening cyanosis, or arrhythmia requires complete right and left heart catheterization:
  • Diagnostic Hemodynamic Cut-offs: A mean Fontan/cavopulmonary pressure of 15 mmHg or greater (and especially greater than 18 to 20 mmHg) or a Transpulmonary Gradient (TPG = mean PA pressure minus LA/wedge pressure) greater than 6 to 8 mmHg confirms a failing circuit.
  • Zero-Tolerance for Anatomical Gradients: In a passive non-pulsatile circuit, even a 1 to 2 mmHg pressure gradient across the Fontan conduit, Glenn anastomosis, or branch pulmonary arteries represents a severe hemodynamically significant obstruction that mandates percutaneous stenting.
  • Collateral Mapping: Identifies venovenous collaterals (from SVC/innominate/IVC to pulmonary veins/LA, causing severe cyanosis) and aortopulmonary collaterals (APCs) (causing competitive pulmonary flow and single-ventricle volume overload).
  • Cross-Sectional Imaging (CMR and MDCTA): CMR quantifies single-ventricle volumes, ejection fraction, AV valve regurgitant fraction, collateral flow fraction, and T2-weighted Dynamic Contrast MR Lymphangiography (mapping thoracic duct leak pathways); MDCTA evaluates stents, conduit thrombus, and pulmonary embolism.
  • End-Organ Biomarkers and Liver Surveillance: Serum Albumin, Total Protein, IgG, lymphocyte count, and Fecal Alpha-1 Antitrypsin clearance (for PLE); NT-proBNP; and annual FALD surveillance (LFTs, GGT, Platelet count, Alpha-Fetoprotein [AFP], and Liver Ultrasound / Transient Elastography [FibroScan]).

IVMECHANISM-SPECIFIC MANAGEMENT STRATEGIES (ESC 2020 / AHA 2019)

AHemodynamic and Pharmacological Optimization

  • Judicious Diuretic Therapy: Loop diuretics (Furosemide/Torsemide) combined with Mineralocorticoid Receptor Antagonists (Spironolactone 25 to 100 mg/day) are the cornerstone for controlling ascites and peripheral edema; however, over-diuresis must be avoided because excessive reduction in central venous pressure abolishes the passive transpulmonary gradient and precipitates acute low cardiac output and prerenal azotemia.
  • Pulmonary Vasodilators (Lowering the “Critical Bottleneck” PVR — Class IIb in ESC 2020): Because pulmonary vascular resistance is the primary determinant of single-ventricle preload in a Fontan circuit, PDE-5 Inhibitors (Sildenafil, Tadalafil, or Udenafil [studied in the Phase III FUEL Trial, 2020]) and Endothelin Receptor Antagonists (Bosentan [TEMPO Trial] or Macitentan) are used to lower PVR and improve submaximal exercise capacity in patients with elevated Fontan pressures and low PAWP.
  • Systemic Ventricular GDMT: While empirical ACE inhibitors showed no benefit in single-ventricle and preserved-EF Fontan cohorts (e.g., the Pediatric Heart Network infant single-ventricle enalapril trial), ACEi/ARBs/ARNI, Beta-blockers, MRAs, and SGLT2 Inhibitors (Empagliflozin/Dapagliflozin) are utilized in Phenotype I (systolic dysfunction).

BTargeted Management of Lymphatic Failure (PLE and Plastic Bronchitis)

  • Medical Therapy for Protein-Losing Enteropathy (PLE):
    • Dietary Modification: High-protein (greater than 2 g/kg/day), low-long-chain-fat, high-Medium-Chain Triglyceride (MCT) diet (because MCTs are absorbed directly into the portal venous bloodstream rather than intestinal lacteal lymphatics, bypassing and decompressing engorged gut lymphatics).
    • Targeted Anti-Inflammatory and Endothelial Therapy: Oral Controlled-Ileal-Release Budesonide (3 to 9 mg/day) suppresses enteric mucosal inflammation and restores tight-junction integrity (requires monitoring for systemic cushingoid effects because hepatic congestion impairs first-pass steroid metabolism); High-Dose Spironolactone; Subcutaneous Unfractionated Heparin (which restores enterocyte membrane heparan sulfate proteoglycans); Octreotide (reduces splanchnic blood and lymphatic flow); and intravenous Albumin + Furosemide infusions with IVIG replacement for severe hypogammaglobulinemia.
    • Acute and Chronic Management of Plastic Bronchitis (PB):
    • Airway Cast Clearance: Nebulized Recombinant Tissue Plasminogen Activator (tPA / Alteplase) (which lyses the fibrin matrix of bronchial casts), nebulized heparin, dornase alfa, hypertonic saline, vest physiotherapy, and urgent rigid/flexible bronchoscopic cast extraction for airway obstruction.
    • Interventional Lymphatic Decompression (Game-Changer for PLE & PB):
    • Percutaneous Lymphatic Embolization: Using intranodal/intrahepatic lymphangiography and thoracic duct cannulation to selectively embolize abnormal peribronchial lymphatic leaks (in Plastic Bronchitis, >85% resolution) or hepatoduodenal/periduodenal lymphatic fistulae (in PLE) using lipiodol, cyanoacrylate glue, and microcoils.
    • Innominate Vein Turn-Down (Hraska Procedure): Surgically disconnecting the thoracic duct-draining left innominate vein from the high-pressure SVC/Glenn and anastomosing it directly to the low-pressure pulmonary venous atrium, decompressing the thoracic duct from 18 mmHg down to 6 mmHg.

CCatheter and Surgical Structural Rescue

  • Relief of Pathway Obstruction (Class I): Balloon angioplasty and endovascular stenting of any Fontan conduit, baffle, or branch pulmonary artery stenosis, and coil embolization of large aortopulmonary collaterals.
  • Creation or Enlargement of a Fontan Fenestration (Class IIa/IIb): Transcatheter needle puncture and stenting to create a 4 to 6 mm fenestration between the Fontan conduit and the systemic atrium decompresses CVP (improving PLE/PB) and increases cardiac output at the cost of mild cyanosis. (Conversely, if severe cyanosis is driven by large venovenous collaterals, transcatheter coil/plug occlusion restores saturation provided baseline Fontan pressure is not prohibitively high.)
  • Arrhythmia Control and Surgical Fontan Conversion: Immediate DC cardioversion and 3D catheter ablation for Intra-Atrial Reentrant Tachycardia (IART). Patients with an obsolete dilated Atriopulmonary Fontan, refractory IART, and preserved ventricular function undergo Surgical Fontan Conversion to an Extracardiac TCPC + Right Atrial Reduction + bi-atrial Cryo-Maze + epicardial dual-chamber pacemaker.

VDEFINITIVE THERAPY: MECHANICAL SUPPORT AND TRANSPLANTATION

  • Indications for Heart (or Combined Heart-Liver) Transplantation: Refractory PLE or Plastic Bronchitis (which resolves completely in over 90 percent of patients once normal low-CVP biventricular physiology is restored by transplant), end-stage systemic ventricular failure, or uncorrectable Fontan hemodynamic failure.
  • Unique Transplant Challenges: High surgical bleeding risk from multiple redo sternotomies and high-pressure collateral vessels, need for extensive pulmonary artery and vena caval reconstruction, high HLA allosensitization (from prior homograft patches and transfusions), and determining when advanced FALD cirrhosis mandates en-bloc Combined Heart-Liver Transplantation (CHLT) rather than isolated heart transplantation.

VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • Mandatory Annual FALD FibroScan and AFP Screening: Because many Indian Fontan survivors were operated at an older childhood age (resulting in longer cumulative pre- and post-Fontan hepatic injury), annual Transient Elastography (FibroScan), liver ultrasound, and serum Alpha-Fetoprotein (AFP) are essential to detect early cardiac cirrhosis and hepatocellular carcinoma.
  • Maximizing Native Fontan Survival: Given the limited availability and high cost of ACHD Heart and Heart-Liver Transplantation in India, aggressive medical and transcatheter palliation—combining Sildenafil + Spironolactone + MCT diet + oral Budesonide, stenting of minor branch PA stenoses, and transcatheter fenestration creation—is the frontline strategy.
  • Nutritional Rehabilitation and Contraceptive Counseling: In Indian children and young adults with PLE, correcting severe protein-calorie malnutrition, fat-soluble vitamin deficiencies (A, D, E, K), and hypocalcemia is critical, alongside proactive counseling against high-risk pregnancy (mWHO Class IV in any failing Fontan).

Key references

  • Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
  • Rychik J, Atz AM, Celermajer DS, et al.: Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association, Circulation, 2019.
  • Book WM, Gerardin JF, Saraf AP, Marie Valente A, Rodriguez FH III: Clinical Phenotypes of Fontan Failure: Implications for Management, Congenital Heart Disease, 2016.
  • Goldberg DJ, Zak V, Goldstein BH, et al. (FUEL Investigators): Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial, Circulation, 2020.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.